PHARMACIE LAMBERT
ActiveSummary
PHARMACIE LAMBERT has been active since 2004 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €482,808 and a net result of -€10,605. Equity has been growing by about 14% per year since 2019. Its solvency ranks better than 72% of 5,036 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
Source: KBO- Status
- Active since 13-01-2004 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 30-09-2025
- Establishment unit
- 2.135.102.335 4031 Liège, since 13-01-2004
- Financial year end
- 30 September
- Peppol
- Reachable since 18-11-2025
Board and ownership
- Pharmacie du LaveuDirector · permanent representative Isabelle MILIS
- PHARMACIE DU LAVEU100%· score 692025 annual accounts of PHARMACIE DU LAVEU
- Isabelle MILIS0.5%annual accounts 30-09-2019
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €422,965
- ▲ 4.9%
- Turnover
- ≈ €1.5m
- estimated
- Loss
- €10,605
- Equity
- €482,808
- ▼ 2.1%
- Total assets
- €830,901
- ▼ 7.1%
- Employees on 30-09-2025
- 6
- =
Score breakdownraises riskSector: Retail trade (NACE 47)lowers riskEquity €482,808 (58.1% of total assets)Founded in 2004Liquidity: current ratio 1.71, cash €153,918Show the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 71% of them on solvency, 61% on liquidity, 47% on profitability and 35% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 38 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
Recent changes
- · Gazette deed Amendment of the articles · Legal-form change · Resignations & appointmentsResignation: Isabelle MILIS (director) · Appointment: Pharmacie du Laveu (director) · Permanent representative: Isabelle MILIS
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as PHARMACIE LAMBERT: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €762,000 and €952,000, founded between 1997 and 2008.
| Company | Total assets | Gross margin |
|---|---|---|
| PHARMACIE LAMBERT Liège | €830,901 | €422,965 |
| PHARMACIE TELLIER CONSEIL Sint-Lambrechts-Woluwe | €940,451 | €486,375 |
| PHARMACIE REMILI-BASTIN Chapelle-lez-Herlaimont | €951,909 | €354,802 |
| Gooreind Pharma Wuustwezel | €791,241 | €487,006 |
| PHARMACIE CENTRALE DE MAURAGE La Louvière | €868,169 | €512,644 |
| GEASSOCIEERDE APOTHEEK PIOT Antwerpen | €784,378 | €504,299 |
| Pharmacie Sacré Liège | €761,678 | €371,790 |
Key facts about PHARMACIE LAMBERT
- What is the company number of PHARMACIE LAMBERT?
- The company number of PHARMACIE LAMBERT is 0862.629.215. The VAT number is the same number with BE in front: BE 0862.629.215.
- Where is PHARMACIE LAMBERT based?
- The registered office is at Route du Condroz 473, 4031 Liège.Company details
- What does PHARMACIE LAMBERT do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMACIE LAMBERT?
- The legal form of PHARMACIE LAMBERT is Private limited company (BV).
- When was PHARMACIE LAMBERT founded?
- PHARMACIE LAMBERT was founded on 13-01-2004.
- Is PHARMACIE LAMBERT still active?
- Yes, PHARMACIE LAMBERT is an active enterprise in the KBO register.
- How many employees does PHARMACIE LAMBERT have?
- PHARMACIE LAMBERT had an average of 5.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does PHARMACIE LAMBERT fall under?
- In its 30-09-2025 annual accounts, PHARMACIE LAMBERT states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of PHARMACIE LAMBERT?
- The turnover in financial year 2025 is ≈ €1.5m. This figure is estimated from the gross margin of €422,965 and 47 comparable companies (NACE 477). It probably lies between €1.2m and €2.5m.
- Is PHARMACIE LAMBERT profitable?
- In financial year 2025, PHARMACIE LAMBERT made a loss of €10,605.
- Where can I find the annual accounts of PHARMACIE LAMBERT?
- PHARMACIE LAMBERT filed 22 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMACIE LAMBERT due?
- PHARMACIE LAMBERT must file the annual accounts for financial year 2026 by 30-04-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.